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Tuberculosis (TB) remains a leading global health problem that is aggravated by emer-
gence of drug-resistant strains, which account for increasing number of treatment- 
refractory cases. Thus, eradication of this disease will strongly require better therapeutic 
strategies. Identification of host factors promoting disease progression may accelerate 
discovery of adjunct host-directed therapies (HDTs) that will boost current treatment 
protocols. HDTs focus on potentiating key components of host anti-mycobacterial 
effector mechanisms, and limiting inflammation and pathological damage in the lung. 
Granulomas represent a pathological hallmark of TB. They are comprised of impressive 
arrangement of immune cells that serve to contain the invading pathogen. However, 
granulomas can also undergo changes, developing caseums and cavities that facilitate 
bacterial spread and disease progression. Here, we review current concepts on the role 
of granulomas in pathogenesis and protective immunity against TB, drawing from recent 
clinical studies in humans and animal models. We also discuss therapeutic potential 
of inflammatory pathways that drive granuloma progression, with a focus on new and 
existing drugs that will likely improve TB treatment outcomes.
Keywords: tuberculosis, Mycobacterium tuberculosis, granuloma, inflammation, host-directed therapy, drug-
resistant TB, MDR-TB, tissue pathology
iNTRODUCTiON
One-third of the world population is latently infected with Mycobacterium tuberculosis (Mtb), the 
causative agent of tuberculosis (TB). About 5–10% of the latently infected population develops active 
TB and manifest clinical signs of the disease (1, 2). Active TB is estimated to cause 1.5 million deaths 
annually, making it one of the most deadly communicable diseases worldwide (3). Efforts to control 
and eradicate TB are hampered by coinfection with the human immunodeficiency virus (HIV) and 
emergence of drug-resistant bacteria. In 2014, 480,000 new cases of multidrug-resistant (MDR) TB 
were reported, and an estimated 9.7% of the MDR-TB patients have extensively drug-resistant (XDR) 
TB, characterized by resistance to second-line drugs and poor treatment outcomes (3). Therefore, 
there is an urgent need to develop new therapeutic drugs, an effective vaccine, and reliable diagnostic 
tests for latent disease in order to achieve the health targets of the newly adopted sustainable develop-
ment goals (SDGs) aimed at ending the TB epidemic by 2030 (3).
The current standard first-line treatment regimen consisting of isoniazid, rifampicin, ethambutol, 
and pyrazinamide requires long duration of treatment (at least 6 months for first-line TB therapy and 
18–20 months for MDR-TB therapy) to achieve sterilization of infection. Moreover, the toxic side 
FiGURe 1 | Basic structure of TB granuloma. A granuloma is a compact immunological structure rich with macrophages at the center. Macrophages can 
undergo specialized transformation differentiating into other cell types, such as epithelioid cells, multi-nucleated giant cells, and foamy macrophages that are 
accumulated with lipid droplets. A lymphocytic cuff that is largely comprised of B and T cells characterizes the periphery of the granuloma. Many other cell types are 
known to constitute a granuloma, including neutrophils, dendritic cells, natural killer (NK) cells, and fibroblasts.
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effects of drugs may lead to non-compliance to treatment, thus, 
opening a window for development of drug resistance. Hence, 
novel treatment strategies are required to shorten the duration of 
treatment and improve treatment outcomes particularly in drug-
resistant patients. The use of adjunctive host-directed therapies 
(HDTs) that seek to limit lung pathological damage and boost 
the host protective armory against Mtb infection is an attractive 
avenue requiring more research exploration (4–6). In this review, 
we discuss the role of the granuloma in the progression of TB 
disease and review HDTs that target pathways implicated in 
severe inflammation during TB disease.
iNiTiATiON OF GRANULOMA 
FORMATiON: A CONTRiBUTiON  
OF iNNATe CeLLS
A prominent pathological feature of TB is the formation of granu-
lomas, driven by both bacterial and host factors in the lungs of 
infected patients (Figure 1) (6, 7). A granuloma is an organized 
and compact immunological structure rich with immune cells, 
such as macrophages, monocytes, dendritic cells (DCs), neutro-
phils, epithelioid cells, foamy macrophages, and multi-nucleated 
giant cells (8, 9). This initial structure is surrounded by a layer of 
lymphocytes giving it an organized solid structure (8, 9).
Early events that lead to granuloma formation were eluci-
dated through a study by Davis and Ramakrishnan that utilized 
a transparent embryonic zebrafish model of Mycobacterium 
marinum (M.m) expressing fluorescent proteins (10). The study 
showed that bacteria freely replicate within macrophages and 
that mycobacteria direct recruitment and motility of uninfected 
macrophages into the surrounding areas of infected cells using 
the ESX-1/RD1 virulence locus (10). Moreover, mycobacterial 
virulence protein ESAT-6 induces the secretion of host matrix 
metalloproteinase-9 (MMP-9) by epithelial cells to drive the 
recruitment of new macrophages into the granuloma (11, 12). 
Studies conducted in humans and animal models have confirmed 
the crucial role of MMP-9 in pathogenesis of TB (7, 13–15). 
Infected macrophages departing the primary granuloma are 
involved in establishing secondary granulomas, thus, promoting 
early dissemination of infection (10). Mycobacterial cell wall gly-
colipid, trehalose 6,6′-dimycolate (TDM), is also known to trig-
ger immunogenic responses that lead to granuloma formation in 
mice. The TDM-driven granulomatous response is initiated and 
maintained by pro-inflammatory cytokines (TNF-α and IL-6) 
and complement C5 and can be down modulated by lactoferrin 
(16, 17).
Macrophages within the granuloma develop into specialized 
cell types, such as epithelioid macrophages, foamy macrophages, 
and multi-nucleated giant cells that form after fusion of plasma 
membranes of multiple macrophages (18). Mycobacterial 
lipids, such as oxygenated mycolic acid, have been shown to 
trigger the differentiation of human monocyte-derived mac-
rophages (MDM) into foamy macrophages in vitro (19). Murine 
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macrophages infected with bacillus Calmette-Guérin (BCG) 
differentiate into foamy macrophages through a signaling pro-
cess that is mediated by toll-like receptor 2 (TLR2) (20). Studies 
conducted in humans and murine models have associated foamy 
macrophages with necrotic regions of the granuloma (19). A 
recent study by Berg et al. showed that snapc1b zebrafish mutants, 
which were identified in a genetic forward screen by Tobin et al., 
were hypersusceptible to M.m infection due to early breakdown 
of granulomas that resulted in release of mycobacteria to a growth 
permissive extracellular milieu (21, 22). In addition, macrophages 
from snapc1b mutants displayed vacuolated morphology and had 
reduced speed of homeostatic migration due to accumulation of 
undigested debris in the lysosomes (22). This indicates that the 
migratory capacity and lysosomal functionality of macrophages 
is crucial for control of bacterial proliferation.
Dendritic cells are among the early arrivals at the site of infection 
where they partake in sampling of antigen by engulfing bacteria, 
bacterial products, and infected dying cells, leaving the site of 
infection and migrating via the lymphatic system to the draining 
lymph nodes where they possibly trigger acquired immunity (23). 
A study by Harding et al. showed that inflammatory DCs infected 
with BCG associated with bacteria-specific T cells, resulting in 
the formation of new multi-foci lesions, demonstrating their role 
in granuloma reformation (24). Moreover, Mtb can modulate DC 
function by impairing antigen presentation and migration to the 
draining lymph nodes, thereby delaying the development of the 
adaptive immune response required to arrest bacterial prolifera-
tion (23, 25).
Diverse myeloid cell subsets contribute to the granuloma and 
drive unique pathological outcomes during TB disease. Studies 
conducted in murine and non-human primate models showed 
that polymorphonuclear neutrophils (PMNs) are recruited early 
to the lung during virulent Mtb infection (26–29). PMNs either 
confer host protection by driving T-cell priming and granu-
loma formation or promote disease severity depending on the 
genetic background of experimental mice (30–34). PMNs have 
been implicated in lung damage during TB disease in studies 
conducted in mice (35) and humans (36). Kinetics studies in the 
lungs of C57BL/6 and 129S2 mice detected an accumulation of 
myeloid-derived suppressor cells (MDSCs) that drive inflamma-
tory responses to Mtb and restrict selected T-cell responses (37, 
38). MDSCs have also been identified in pleural effusions and 
blood of TB patients (39, 40).
The final step in granuloma formation is the arrival of T and B 
cells that form the lymphocytic cuff at the periphery of the granu-
loma giving it a solid intact structure (41–45). The arrival of Mtb-
specific T cells in the lungs coincides with the arrest of bacterial 
proliferation 14–21 days after initiation of infection by producing 
TNF and IFN-γ that enhance macrophage microbicidal activity 
(1, 46–51). Mice deficient of CD4+ T cells are susceptible to Mtb 
infection and have decreased cellular infiltration to the lungs 
(52). Other T cell subsets involved in immune response to Mtb 
infections in mice and humans include γδ T cells, CD8 T cells 
and, CD1-restricted CD4/CD8 double negative T cells (53, 54). 
Development of an optimal Th1 and Th17 immune responses is 
critical for long-term control of Mtb infection (55, 56). However, 
an exuberant immune response may be detrimental to the host 
due to excessive tissue inflammation; hence, a more balanced 
Th1/Th2/Th17 immune response is more desired to drive host 
protection, while limiting tissue pathology.
THe ROLe OF iNFLAMMATORY 
PATHwAYS iN GRANULOMA 
DiSSOCiATiON AND DiSeASe 
PROGReSSiON
As TB disease progresses, the granuloma may undergo complex 
remodeling events that result in the formation of a caseum, a 
cheese-like cellular structure containing necrotic material at 
the center of the granuloma that is rich in lipids and reportedly 
hypoxic. Analysis of human TB granulomas by genome-wide 
microarray found genes associated with lipid sequestration and 
metabolism to be highly expressed in caseous granulomas (57). 
Moreover, immunohistological studies revealed that cells sur-
rounding the caseum expressed high levels of proteins involved 
in lipid metabolism, such as adipophilin, acyl-CoA synthetase 
long-chain family member 1, and saposin C (57). Destruction of 
the caseum results in liquefaction and eventually to granuloma 
cavitation, which permits the release of infectious Mtb into 
the airways where they are aerosolized in cough droplets and 
can facilitate bacterial transmission to new hosts (57, 58). The 
events that lead to granuloma collapse and spread of bacteria 
are depicted in Figure  2. Histological studies conducted in 
non-human primates (NHP) have elucidated the complexities 
of granuloma dissociation in relation to disease progression. 
A study by Lin et al. found that a discordance exists between the 
extent of granuloma destruction and the clinical state of disease 
in NHPs (59). Moreover, a subsequent study by Lin et al. showed 
that each individual granuloma within the same host behaves 
independently of others, suggesting that infected individuals have 
a heteregenous mixture of granulomas with varying immune pro-
file and competence to control the bacteria (60). Hence, the fate 
of a few granulomas within the host seems to drive the majority 
of clinical morbidities associated with the disease (57, 60, 61).
Dissociation of the granuloma is driven by both host and 
mycobacterial factors that induce different cell-death modali-
ties in infected cells. Infected granuloma macrophages can 
die either by apoptosis or necrosis. Apoptotic cell death seems 
to favor the host by keeping the bacteria encased within dead 
macrophages that can be readily phagocytosed by newly arriving 
uninfected macrophages. In contrast, necrotic cell death, which 
is characterized by the loss of cell membrane integrity, results in 
leakage of the bacteria into the growth permissive extracellular 
environment where the bacteria thrive by adopting a character-
istic cording phenotype, making it difficult for the bacteria to 
be engulfed by new macrophages (62, 63). Host-derived TNF-α 
has been implicated in causing macrophage necrosis during Mtb 
infection (64, 65). Excessive production of TNF-α drives necrosis 
of infected macrophages through a programmed pathway called 
necroptosis that involves the activation of receptor activating 
protein 1 (RIP1) and RIP3 kinases via the production of reactive 
oxygen species (ROS) by the mitochondria (64, 65). TNF-α-
induced macrophage necrosis is modulated by mitochondrial 
FiGURe 2 | Granuloma development during TB progression. The initial stages of TB infection involve inhalation of M. tuberculosis bacilli into the lung and 
phagocytosis by resident alveolar macrophages. Mtb elicits local inflammatory response resulting in the recruitment of monocytes and macrophages and other 
innate immune cells to the site of infection. The macrophages further differentiate into other specialized cells, such as epithelioid macrophages, foamy macrophages, 
and multi-nucleated giant cells. Upon induction of adaptive immunity, the granuloma gets a peripheral lymphocytic cuff mainly characterized by B and T cells. This is 
the balanced solid state in which many granulomas persist and restrict the bacilli at their center. However, as the disease progresses, increased necrotic breakdown 
of granuloma cells leads to the accumulation of caseum, which may result in cavitation of granulomas. Ultimately, as the granuloma cavitates and collapses into the 
lung, Mtb bacilli are released into the airway.
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cyclophilin D via the formation of the mitochondrial perme-
ability transition pore complex and the production of ceramide 
by the acid sphingomyelinase (65). Inhibition of cyclophilin D 
with alisporivir and inactivation of acid sphingomyelinase with 
an anti-depressant drug desipramine restored resistance to M.m 
infection in zebrafish (65).
Studies conducted in mice and zebrafish have shown that 
mycobacterial virulence factors can modulate macrophage necro-
sis by generating specific eicosanoids from arachidonic acid (AA) 
(21, 66). Virulent Mtb H37Rv strain induces the production of 
lipoxin A4 (LXA4) by 5- and 15-lipoxygenases to promote necro-
sis, while H37Ra mutants induced the synthesis of pro-apoptotic 
prostaglandin E2 (PGE2) by cyclooxygenase (COX) 1 and 2 and 
prostaglandin synthases (66–68). Mice lacking 5-lipoxygenase 
(ALOX5−/−) are more resistant to infection with Mtb H37Rv 
strain, indicating that LXA4 is detrimental to the host (21). The 
contribution of eicosanoid metabolites in susceptibility to myco-
bacterial infection was confirmed in a genetic screening study 
that aimed to identify mutant zebrafish that were hypersuscep-
tible to M.m infection (21). The study identified leukotriene A4 
hydrolase (LTA4H), an enzyme involved in the production of leu-
kotriene B4 (LTB4) as a key determinant of host susceptibility to 
M.m infection (21). LTA4H mediates host susceptibility through 
two mechanisms that deregulate TNF-α activity: excess LTA4H 
causes overproduction of LTB4 that drives exuberant production 
of TNF, while low or absence of LTA4H induces the production 
of anti-inflammatory LXA4 that suppresses TNF activity leading 
to uncontrolled bacterial proliferation and macrophage necrosis 
(21, 64). Similar genetic variants encoding for low or high LTA4H 
expression have been identified in humans, and individuals who 
are homozygotes for low or high expression variants of LTA4H 
get severe TB meningitis with high mortality rate, while heterozy-
gotes with intermediate LTA4H expression get protection (21, 
64). Translation of these observations had huge implications for 
therapy as demonstrated in a Vietnamese cohort of TB meningitis 
in which adjunctive therapy with broadly anti-inflammatory 
glucocorticoids was beneficial to a group of patients with high 
LTA4H expression, while deleterious to patients with low LTA4H 
expression (21, 64).
A recent study by Marakalala et  al. characterized protein 
and lipid signatures associated with granuloma progression by 
analyzing different granuloma types (intact, caseous, and cavitary 
granuloma) from tissue obtained from patients who underwent 
surgery due to severe lung disease (69). This study utilized 
laser-capture microdissection, mass spectrometry, and confocal 
microscopy to generate a molecular map of different regions of 
each granuloma type. The study identified over 3000 proteins that 
were differentially expressed between different regions of granu-
loma types (69). The study found more proteomic diversity within 
rather than between different granuloma types. Importantly, the 
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proteomic profiles of caseous and cavitary centers were com-
posed largely of pro-inflammatory pathways, including proteins 
that release pro-inflammatory eicosanoids from AA metabolism 
(69). In contrast, cellular regions found at the periphery of the 
granulomas displayed a more anti-inflammatory signature 
characterized by the abundance of pathways involved in normal 
cellular biogenesis and some enzymes involved in the synthesis 
of prostanoids (69). Together, these data suggest that spatial 
organization of inflammatory responses within the granuloma 
may determine the pathologic response to TB.
THe GRANULOMA: iS iT HOST 
PROTeCTive OR DeTRiMeNTAL?
Initially, the granuloma was thought to be a solely host protective 
structure that “walls off ” infecting bacteria (70, 71). However, 
we argue that the granuloma may represent a standoff between 
two warring camps: the immune response trying to kill the 
invading bacteria and the bacteria seeking to defend itself and 
establish a niche where it can thrive. Earlier histological studies 
conducted on tuberculous lungs obtained from autopsies in the 
pre-chemotherapy era chronicled a series of events associated 
with granuloma destruction (72, 73). Areas of the granuloma that 
had undergone caseation were correlated with increased bacterial 
load, while areas with intact granulomas had reduced bacterial 
numbers, thus, suggesting that the integrity of the granuloma is 
critical for control of bacterial proliferation (72, 73). This was fur-
ther corroborated by findings in a zebrafish model, where it was 
shown that the onset of granuloma caseation is linked to uncon-
trolled bacterial proliferation (74). Moreover, mice deficient in 
TNF (48, 49, 75–79), IFN-γ (80), IL-12 (81), signal transducer and 
activator of transcription 4 (STAT4) (82), and myeloid differentia-
tion primary-response protein 88 (MYD88) (83–85) had poorly 
formed granulomas and were highly susceptible to Mtb infection, 
thus, giving more credibility to the host-protective nature of 
granulomas. Although gene deficient mice are hypersusceptible 
to Mtb infection, the mechanism for their susceptibility may 
not depend on granulomatous responses but be driven by the 
impaired ability of infected macrophages to kill the bacteria (48).
Findings generated over the previous decade suggest that Mtb 
orchestrates the early events of granuloma formation for its own 
benefit, has adapted to life in the granuloma, and has developed an 
arsenal of strategies to evade host-offensive mechanisms. Recent 
technological advances have enabled us to chronicle the early 
events of granuloma formation in the context of innate immunity 
using dynamic imaging tools in a zebrafish model infected with 
M.m (10, 86). Mycobacteria coordinate granuloma formation by 
driving the recruitment and chemotactic motility of uninfected 
macrophages to the granuloma by deploying the ESX-1 secretory 
system encoded by the RD1 virulence locus (10). The recruitment 
of uninfected macrophages to the granuloma is further enhanced 
by the secretion of MMP-9 by epithelial cells activated by the 
mycobacterial virulence factor ESAT-6 (11, 12). MMP-9 has been 
identified as a biomarker for severe TB meningitis and is associated 
with increased mortality in human patients (13, 15). Interestingly, 
ESAT-6 has also been shown to induce apoptosis of infected cells 
in vitro (74, 87–89). The bacteria seem to be able to persist within 
the hostile environment of the granuloma as indicated by the 
propensity of newly infected macrophages to migrate to existing 
granulomas than avoid them in both zebrafish and mice with 
mature granulomas (90, 91). Thus, the ability of the bacteria to 
coordinate both recruitment and death of macrophages suggests 
that the bacteria are actively attempting to create an environment 
ideal for their dissemination and proliferation.
Mycobacteria have adapted to survive in the hostile envi-
ronment by entering a state of non-replicating persistence 
characterized by slow growth and metabolic shift that reduces 
their susceptibility to environmental pressure (92). Moreover, 
the bacteria have developed strategies to survive the hypoxic 
environment encountered in caseous granulomas by inducing 
complex transcriptional networks like DosR regulon (93, 94) and 
angiogenesis to improve the transport of oxygen to the hypoxic 
granuloma (95). Suppression of granuloma associated angio-
genesis by administration of VEGFA inhibitor reduced bacterial 
burdens and acted synergistically with first-line drugs to kill the 
bacteria (95). A study by Zhang et al. identified a set of genes (the 
“counteractome”) required by Mtb to survive the immunological 
stress mediated by CD4+ T cells in mice (96). CD4+ T cells starve 
Mtb of exogenous tryptophan, and deletion of trpE gene required 
for bacterial tryptophan biosynthesis rendered Mtb susceptible 
to the immunological stress (96). Interestingly, a combination of 
IFN-γ administration and inhibition of TrpE by a small molecule 
6-FABA resulted in synergistic killing of Mtb in vitro, suggesting 
that inhibitors of the Mtb “counteractome” can be explored as 
drug candidates that could potentiate anti-mycobacterial immu-
nity (96).
TARGeTiNG iNFLAMMATORY PATHwAYS 
TO DeveLOP HOST-DiReCTeD 
THeRAPieS FOR TB
One of the major challenges associated with current TB treat-
ment protocols is the lengthy duration of therapy that causes poor 
compliance of patients, resulting in increasing cases of MDR- and 
XDR-TB and high mortalities among the treatment-refractory 
patients (6). In order to achieve the WHO goal to eradicate TB by 
2050, we need new treatment strategies that will boost currently 
available drugs, shorten the duration of treatment, and ameliorate 
inflammation and tissue damage. One strategy that is showing 
greater promise of assisting in the fight against TB is the develop-
ment of HDTs that could be used as adjunctive therapy in combi-
nation with the currently available standard treatment regimens. 
HDTs are aimed at augmenting the host’s immunological defense 
mechanisms and reducing excessive tissue pathology, culminat-
ing in improved clinical outcomes reflected in reduced duration 
of treatment and reduced morbidity and mortality (6). A wide 
range of HDTs are currently at varying stages of development and 
clinical testing, including repurposed drugs for diabetes, epilepsy, 
hypercholesterolemia, asthma, cancer, and arthritis (6).
The focus of this section is to discuss recent advances in the 
development of HDTs targeting inflammatory pathways associ-
ated with granuloma dissociation for which proof-of-principle 
has been achieved in animal models or clinical settings (Table 1). 
TABLe 1 | List of drugs inhibiting the inflammatory pathways implicated in granuloma dissociation with proven efficacy in animal models [adapted from 
Ref. (2, 6)].
Drug/compound Potential target/
pathway
Mechanism of action Reported outcomes Development 
stage
Etanercept TNF-α Blocks excess TNF-α Reduced bacterial burdens and lung damage Preclinical
Zileuton ALOX5 Inhibits the synthesis of inflammatory eicosanoids by 
blocking the activity of lipoxygenases
Reduced bacterial burdens and increased 
survival of susceptible mice
Preclinical
Ibuprofen Eicosanoid pathway Limits inflammation by possibly modulating the 
production of anti-inflammatory eicosanoids
Increased survival of Mtb-infected mice and 
reduced tissue inflammation
Preclinical
Simvastatin Cholesterol 
biosynthesis
Blocks the biosynthesis of cholesterol and augments 
autophagy and phagosome–lysosome maturation
Increased survival of Mtb-infected mice and 
ameliorated tissue pathology
Preclinical
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To have the full view of progress, made to date to develop and 
test HDTs, readers are referred to other extensive reviews (2, 5, 
6, 97–99).
Targeting TNF to Limit Tissue Pathology
Although TNF is required to induce macrophage-killing activi-
ties (48, 49, 77), excessive- or low-TNF production is detrimental 
to the host causing augmented tissue pathology (21, 64, 65). 
Inhibition of TNF-α activity has been successfully used to treat 
inflammatory diseases, like rheumatoid arthritis (RA), Crohn’s 
disease, and psoriasis (5). Hence, blocking the activity of TNF 
has been explored as a potential host-directed therapy for TB. 
Treatment of Kramnik mice with a TNF-α inhibitor etanercept 
in conjunction with standard TB treatment reduced pulmonary 
bacterial burden and ameliorated lung pathology (100). However, 
the relapse of some of the mice treated with etanercept adjunctive 
therapy is of concern, albeit the relapse being lower compared 
with mice that received the standard treatment alone (100). The 
safety risks of using TNF-α inhibitors have also been demon-
strated in human studies where patients receiving TNF-α inhibi-
tors for chronic inflammatory disease like RA and Crohn’s disease 
can develop reactivation of TB disease (101, 102). Moreover, the 
presence of polymorphisms in LTA4H that skew TNF production 
is another confounding factor that needs to be addressed before 
considering the use of TNF-α inhibitors as adjunctive therapy in 
humans. Therefore, more studies are still required to improve the 
safety profile of TNF inhibitors.
Pro-inflammatory eicosanoids: Key 
Mediators of Granuloma Dissociation and 
inflammation during TB
As discussed above, pro-inflammatory eicosanoids have been 
implicated in disease progression by driving necrotic cell death 
and contribute to increased mortality of mice infected with 
Mtb. Recently, eicosanoids have been associated with the type I 
IFN response and contribute to the outcomes of both Mtb and 
influenza infections (103, 104). Studies conducted in mice and 
humans have demonstrated a deleterious role for type I IFNs to 
the host during Mtb infection (105–112). IFN-α/β have been 
shown to block the production of host protective cytokines IL-1α 
and IL-1β both in vitro using human and murine cells and in vivo 
using mice (113–115). Interestingly, IL-1α and IL-1β negatively 
regulate type I IFNs in murine and human macrophages and 
inhibit pro-bacterial effects downstream of IFN-β (103). IL-1-
driven PGE2 production counter-regulates the function of type I 
IFN and is beneficial to the host as demonstrated in mice double 
deficient for IL-1R/IFNAR1 (103). This counter-regulatory 
mechanism has been shown to be at play in both human and 
murine cells infected with Mtb (103). The direct administration 
of PGE2 or blocking 5-lipoxygenase with zileuton rescued the 
highly susceptible IL-1-knockout mice from Mtb infection and 
reduced bacterial burdens (103). Therefore, manipulating the 
balance of eicosanoid by administering PGE2 or zileuton might 
offer an attractive adjunctive therapy for TB that could be used 
to improve the disease outcome (103). Interestingly, zileuton has 
already been approved for clinical use in asthma (103). The role of 
eicosanoids in driving granuloma dissociation and the potential 
benefits of targeting specific proteins as candidates for HDTs is 
summarized in Figure 3.
Inhibition of inflammatory eicosanoids with non-steroidal 
anti-inflammatory drugs (NSAIDs), such as ibuprofen, has been 
used as monotherapy for TB in mice with great success (116, 
117). Treatment of C3HeB/FeJ (Kramnik) mice with ibuprofen 
increased survival of Mtb-infected mice by limiting severe tissue 
pathology and reducing bacterial load compared with untreated 
control mice (116). This study established a proof-of-principle for 
the use of NSAIDs as a host-directed adjunctive therapy for TB 
that can be used in combination with standard chemotherapeutic 
drugs.
Targeting Lipids Modulates inflammation 
and improves Treatment Outcomes
The role of lipids in the dissociation of the granuloma has been 
demonstrated in a study that utilized genome-wide screening 
to determine the levels of genes involved in lipid metabolism in 
human TB lung tissues (57). This study found that genes involved 
in lipid metabolism were highly expressed in caseous granulo-
mas, and this was further proven by immunohistological stain-
ing that confirmed the abundance of proteins involved in lipid 
metabolism in caseous regions of the granuloma (57). Mtb can 
utilize host cholesterol to maintain persistent chronic infection. 
Moreover, lipid bodies present within foamy macrophages have 
been shown to play a role in reactivation of latent TB disease (118, 
119). Therefore, lipids have been targeted as possible host-directed 
therapy for TB disease using statins; competitive inhibitors of 
HMG-CoA reductase, an enzyme involved in the biosynthesis 
of cholesterol (120). Statins have been used clinically to treat 
FiGURe 3 | Targeting inflammatory proteins as host-directed therapies (HDTs) for TB to ameliorate tissue inflammation. Arachidonic acid (AA) is 
metabolized by 5-lipoxygenase (5-LO) to produce leukotriene A4 (LTA4), a substrate in the subsequent step that is catalyzed by leukotriene A4 hydrolase (LTA4H) to 
produce the highly inflammatory leukotriene B4 (LTB4). High levels of LTB4 drive excessive TNF-α production by macrophages that may trigger necrotic cell death. 
Necrotic cell death leads to granuloma dissociation resulting in the formation of caseums and eventually cavities after the necrotic center collapses into the airways. 
Type I IFNs block the production of host protective IL-1α and IL-1β in vitro and in vivo resulting in reduced production of PGE2. Targeting specific inflammatory 
proteins with chemical inhibitors or antibodies could be a possible HDT aimed at limiting tissue inflammation and improve treatment outcomes. The proof-of-
principle for the interventions depicted in the schematic has been established in animal models.
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patients with coronary disorders and hypercholesterolemia (121) 
and have been shown to possess immunomodulatory and anti-
inflammatory properties (122, 123).
In vitro studies conducted using peripheral blood mono-
nuclear cells (PBMCs) and MDM isolated from patients with 
familial hypercholesterolemia who underwent statin therapy 
were found to be resistant to Mtb infection compared with cells 
from healthy controls (124). In addition, treatment of mice 
with simvastatin prior to Mtb infection increased survival due 
to decreased lung bacterial load and improved pathological 
outcomes (124). The host-protective mechanism was shown 
to be mediated by the ability of statins to promote phagosomal 
maturation and autophagy (124). Statins have also been shown to 
enhance the bactericidal activity of first-line drugs in vitro using 
infected macrophages (125) and in vivo using a mouse model of 
chronic TB infection (126). A recent study by Dutta et al. showed 
that using simvastatin as an adjunctive therapy in combination 
with the first-line drug rifampicin shortened the duration of 
treatment in mice (127). Therefore, statins appear to be attractive 
candidates for host-directed therapy for TB. However, more work 
is still required to assess the safety, dosage, and efficacy of statins 
in humans infected with Mtb.
SUMMARY AND CONCLUDiNG ReMARKS
Tuberculosis still remains a huge public health problem with high 
mortality rate in infected individuals. Moreover, drug resistance 
has emerged as an enormous problem exerting more strain on 
health services. This has necessitated an urgent need to develop 
new drugs that not only target the pathogen but also helps to 
boost the host’s natural ability to fight the infection. The site that 
represents a standoff between the host and the pathogen as they 
seek to establish dominance is the granuloma; a key immuno-
logical structure composed of innate and adaptive cells of the 
immune system. Initially, the granuloma was thought to provide 
host protection by “walling off ” the bacteria; however, evidence 
emerging from recent studies indicates that the granuloma may 
be manipulated by the mycobacteria to achieve its dominance in 
the host (70, 71, 128). Studies have demonstrated that virulence 
factors secreted by Mtb via the ESX-1 secretory system drive the 
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recruitment of macrophages to the granuloma and influence the 
cell-death modality of infected macrophages by favoring necrosis 
mediated by the RIP1/RIP3 necroptosome (64, 65). Moreover, 
ESAT-6 has been shown to induce the secretion of MMP-9 by 
epithelial cells to further drive the recruitment of macrophages 
to the granuloma (11, 13–15).
The granuloma can undergo complex remodeling events 
driven by both bacterial and host factors resulting in some 
structural changes that coincide with TB disease progression. 
Studies have been conducted to understand the mechanism driv-
ing granuloma dissociation during TB disease (57, 69). Excessive 
TNF-α production has been implicated in the destruction of 
the granuloma in zebrafish (64, 65). Caseating regions of the 
granuloma have an abundance of proteins associated with lipid 
metabolism (57). Moreover, pro-inflammatory proteins, such as 
LTA4H, were highly expressed in caseous regions of the granu-
loma compared with cellular regions and associated with TNF-α 
expression (69). Hence, factors that drive granuloma dissociation 
have been explored as potential HDTs that could be used to 
improve treatment outcomes in conjunction with currently avail-
able standard treatment regimen. More studies are still required 
to further expand our knowledge of the molecular factors that 
sway the double-edged nature of the granuloma in favor of the 
host or the pathogen.
Blocking TNF-α with etanercept in the presence of first-line 
drugs proved beneficial to host by reducing bacterial load and 
limiting tissue pathology (100). Moreover, manipulating the 
balance of pro-inflammatory eicosanoids by directly administer-
ing PGE2 or using zileuton to block 5-lipoxygenase increased 
the survival of highly susceptible mice infected with Mtb (103). 
Finally, treatment of Mtb-infected mice with statins in the pres-
ence or absence of first-line TB drugs increased survival and 
reduced the duration of TB therapy (124, 127). These studies have 
established a proof-of-principle for the use of drugs that inhibit 
the pro-inflammatory pathways involved in granuloma dissocia-
tion in murine models. However, further studies are required to 
determine the safety, dosage, and efficacy of these drugs for use 
in humans. Challenges encountered with the administration of 
glucocorticoid steroids in patients with TB meningitis suggests 
that caution must be exercised in the roll-out of HDTs for TB 
and that perhaps personalized medicine might offer a better 
treatment approach.
Although not discussed in this review, a number of drugs 
currently used clinically to treat diabetes (115), cancer (95, 129), 
and hypertension (130) have shown some promise in anti-TB 
defense and can be repurposed for use as adjunctive therapy 
for the disease (2, 6). These will require more testing to ensure 
their efficacy and safety to use as adjunctive therapy for TB at 
the currently approved clinical dosages. To bolster our arsenal 
of adjunctive HDTs for TB, we need to amplify our efforts to 
identify potential new targets and improve our understanding of 
the complex processes that lead to disease progression at both 
molecular and systemic levels.
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